Azenta, Inc.
PublicAzenta, Inc. is now publicly traded
The data on this page reflects Azenta, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Buyout/LBO
Feb 1, 2022
Est. Valuation at Exit
$3B
Total Funding Raised
$3B
Company Overview
Azenta, Inc. is a biotechnology company that provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies.
AI Layer
Non-AI
Keywords
Azenta, Inc. Comparables
Compare Azenta, Inc. with similar companies based on industry and business-model similarity.
No public comparables are available for Azenta, Inc.. Request access to learn about comparables coverage.
Book a demoFor institutional investors. Book with your work email.
Azenta, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Feb 1, 2022 |
For institutional investors. Book with your work email.
Azenta, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thomas H. Lee Partners | Buyout/LBO |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 30, 2026
On Oct 30th '26, Azenta US, Inc. licenses technology from Elegen Corporation under an exclusive agreement as part of strategic investments in its GENEWIZ business.
- partners_withOct 30, 2026
Azenta, Inc. partners with Elegen Corporation through an exclusive licensing agreement that brings an advanced cell-free DNA synthesis platform into GENEWIZ to improve DNA quality, delivery speed, and manufacturing scalability in Massachusetts on Oct 30th '26.
For institutional investors. Book with your work email.
Azenta, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.